Kids Library Home

Welcome to the Kids' Library!

Search for books, movies, music, magazines, and more.

Available items only
Author Donghi, Monica, author.

Title Patent strategy in pharmaceutical industry : are additional patents valuable? / Monica Donghi.

Publication Info. Baden-Baden : Nomos, 2014.


Location Call No. OPAC Message Status
 Axe JSTOR Open Ebooks  Electronic Book    ---  Available
Edition 1. Auflage.
Description 1 electronic resource (84 pages ).
text txt rdacontent
computer c rdamedia
online resource cr rdacarrier
data file
Series MIPLC studies ; volume 20
MIPLC studies ; volume 20.
Note Originally presented as author's thesis (LL.M.)--Munich Intellectual Property Law Center, 2012.
Bibliography Includes bibliographical references (pages 77-84).
Note Description based on print version record; resource not viewed.
Contents Acronyms and Abbreviations; I. Introduction; II. Background; A. Pharmaceutical Industry -- The Development of a New Drug.; B. New Drug Approval Regulations; C. Generic Drugs Approval.; III. Case Studies-Facts; A. Taxotere; 1. General; 2. Patent Portfolio; a) Process; b) Formulation; c) Combination Therapy; d) New Uses; e) Derivatives; 3. Use of Procedural Provisions: Supplementary Protection Certificates (SPCs)/Patent Term Extension; 4. Conclusion; B. Xalatan; 1. General; 2. Patent Portfolio; a) Process; b) Formulation; c) Combination Therapy; d) New Uses; e) Delivery Devices.
F) Packaged Product3. Use of Procedural Provisions; a) Divisional of Basic Patent; b) Supplementary Protection; 4. Conclusion; IV. Discussion; A. Lifecycle Management: Criticism and Supports; B. Further Filing Strategy: Commercial Value; 1. Innovation Tracks; a) Formulations; b) Combinations; c) Process; d) New Uses; e) Delivery Devices; 2. Xalatan SPC Request: a Case for Competition Law?; C. Patent Strategy and Innovation; D. Summary: Taxotere v Xalatan; E. Conclusion and Suggestions; V. Final Remarks; List of works cited; Periodical Materials in English; Periodical Material in German.
Non Periodical MaterialTable of books; Table of Cases; European Union; EPO Board of Appeal; France; Germany; Italy; United Kingdom; United States; Statutes; Speeches and Reports; Press release; Others.
Summary Dieses Buch untersucht die Lifecycle-Management-Strategien, die von Pharma-Unternehmen eingesetzt werden, um den Wert ihres Produktportfolios zu maximieren. Solche Strategien werden manchmal von Generika-Unternehmen als "evergreening" bezeichnet. Die Analyse erfolgt anhand zwei zufällig ausgewählter "Blockbuster"--Medikamente, Taxotere und Xalatan und konzentriert sich auf zwei dieser Strategien, nämlich die Produktverbesserung und die Produktlinienerweiterung. Reihe Munich Intellectual Property Law Center - MIPLC - Band 20.
Language English.
Subject Drugs -- Patents -- Economic aspects -- European Union countries.
Patent medicines -- Law and legislation -- European Union countries.
Patent medicines -- European Union countries -- Case studies.
Patent medicines. (OCoLC)fst01054844
Patent medicines -- Law and legislation. (OCoLC)fst01054849
European Union countries. (OCoLC)fst01269470
Médicaments -- Brevets d'invention.
LAW -- Commercial -- General.
Genre/Form Case studies. (OCoLC)fst01423765
Other Form: Print version: Patent strategy in pharmaceutical industry Baden-Baden : Nomos, 2014. 9783848709915 (DLC) 2015372690
ISBN 3848709910
Standard No. AU@ 000056062506
AU@ 000062534616
DEBSZ 431647895

Available items only